newsfilter
← Latest News
GlobeNewswire·

Ambrx to Present Preliminary ARX517 First-in-Human Safety, Efficacy, and Pharmacokinetics Data at ESMO 2023

SAN DIEGO, July 28, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., Ambrx (or the "Company") (NASDAQ:AMAM), today announced the acceptance of four abstracts for poster presentation at the European Society for Medical